These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2824523)

  • 1. Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.
    Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H
    J Cancer Res Clin Oncol; 1987; 113(6):593-8. PubMed ID: 2824523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects.
    Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S79-88. PubMed ID: 3842695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites.
    Preiss R; Sohr R; Kittelmann B; Müller E; Haase D
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):156-64. PubMed ID: 2714916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver.
    Noda S; Kawata S; Miyoshi S; Minami Y; Tarui S
    Gastroenterol Jpn; 1989 Apr; 24(2):159-63. PubMed ID: 2545499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients.
    Grieco A; Castellano R; Matera A; Marcoccia S; Di Rocco P; Ragazzoni E; Vecchio FM; Gasbarrini G
    J Gastroenterol Hepatol; 1998 May; 13(5):460-6. PubMed ID: 9641640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.
    Leca F; Marchiset-Leca D; Noble A; Antonetti M
    Eur J Drug Metab Pharmacokinet; 1991; 16(2):107-11. PubMed ID: 1936069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.
    Chlebowski RT; Chan KK; Tong MJ; Weiner JM; Ryden VM; Bateman JR
    Cancer; 1981 Sep; 48(5):1088-95. PubMed ID: 6268277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipyrine metabolism in patients with liver metastases from colorectal cancer.
    Grieco A; Barone C; Coletta P; Castellano R; Ragazzoni E; Cassano A; Astone A; Gambassi G
    Cancer; 1992 Sep; 70(6):1477-82. PubMed ID: 1515999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
    Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
    Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical model for adriamycin (doxorubicin) pharmacokinetics.
    Reich SD; Steinberg F; Bachur NR; Riggs CE; Goebel R; Berman M
    Cancer Chemother Pharmacol; 1979; 3(2):125-31. PubMed ID: 509697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol.
    Johnson PJ; Kalayci C; Dobbs N; Raby N; Metivier EM; Summers L; Harper P; Williams R
    J Hepatol; 1991 Jul; 13(1):120-7. PubMed ID: 1655867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters.
    Johnson PJ; Dobbs N; Kalayci C; Aldous MC; Harper P; Metivier EM; Williams R
    Br J Cancer; 1992 May; 65(5):751-5. PubMed ID: 1316777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.
    Eksborg S; Cedermark BJ; Strandler HS
    Med Oncol Tumor Pharmacother; 1985; 2(1):47-54. PubMed ID: 4058077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General and cardiac toxicity of adriamycinol in rats.
    Danesi R; Del Tacca M; Della Torre P; Bernardini C
    Anticancer Res; 1986; 6(5):967-72. PubMed ID: 3800337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative histochemical study of adriamycin and adriamycinol in rat liver and heart.
    Mazzanti L; Breschi MC; Scalori V; Giovannini L; Mian M
    In Vivo; 1988; 2(3-4):189-93. PubMed ID: 2979836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate.
    Paramsothy J; Strange R; Sharif H; Collins M; Shaw P; Lawrence CM
    Br J Dermatol; 1988 Dec; 119(6):761-5. PubMed ID: 3203069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of oxidative metabolism in adults with hepatocellular carcinoma in the Sudan.
    Homeida MM; Daneshmend TK; Ali EM; Yousif-Elkadaru AG; Arbab BM
    Gut; 1986 Apr; 27(4):382-5. PubMed ID: 3007307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of adriamycin and adriamycinol after intravenous administration of adriamycin to rats with water-deprivation for 48 hours.
    Lee HJ; Lee MG
    Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):299-306. PubMed ID: 9261889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.